SCHEMBL5427738

SCHEMBL5427738

CNC(=O)c1cc(Oc2ccc(C(=O)Nc3cc(C)ccc3O)cc2)ccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 9/20 0.53
▸ BRAF P15056 6/20 0.53
▸ MAPK14 Q16539 4/20 0.52
▸ KCNMA1 Q12791 2/20 0.52
▸ RAF1 P04049 6/20 0.51
▸ EPHX2 P34913 3/20 0.51
▸ MMP13 P45452 1/20 0.49
▸ HDAC1 Q13547 1/20 0.47
▸ PLK4 O00444 2/20 0.47
▸ AURKA O14965 2/20 0.47
▸ MAPK13 O15264 2/20 0.47
▸ MAP4K4 O95819 2/20 0.47
▸ ABL1 P00519 2/20 0.47
▸ LCK P06239 2/20 0.47
▸ FYN P06241 2/20 0.47
▸ LYN P07948 2/20 0.47
▸ RET P07949 2/20 0.47
▸ SRC P12931 2/20 0.47
▸ RPS6KB1 P23443 2/20 0.47
▸ EPHA2 P29317 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5421735 0.92 KDR (0.53) KDRBRAFMAPK14RAF1EPHX2
SCHEMBL5429683 0.90 KDR (0.55) KDRBRAFMAPK14KCNMA1PLK4
SCHEMBL5423396 0.87 BRAF (0.61) KDRBRAFMAPK14RAF1EPHX2
SCHEMBL2605541 0.84 KCNMA1 (0.71) KCNMA1MMP13HDAC1MEN1MAPK1
SCHEMBL167964 0.83 KDR (0.68) KDRBRAFMAPK14RAF1EPHX2
SCHEMBL2747087 0.80 SIRT2 (0.62) KDRBRAFRAF1CSF1RFGFR1
SCHEMBL9968283 0.79 KCNMA1 (0.64) KCNMA1MMP13HDAC1MEN1KMT2A
SCHEMBL14499193 0.79 KDR (0.52) KDRBRAFMAPK14RAF1EPHX2
SCHEMBL5429311 0.79 KDR (0.57) KDRBRAFMAPK14RAF1EPHX2
SCHEMBL19846843 0.79 KCNMA1 (0.62) KCNMA1MMP13HDAC1MEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 — — US claimed
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 — — US disclosed
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 — — US disclosed
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors TIE1, KDR, FLT1 KDR 2/4885BRAF 49/4885MAPK14 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback